Treatment with TFP significantly upregulated the expression levels of pro-ferroptotic proteins, such as FTH1 and NCOA4, while downregulating the expression levels of proteins that reverse ferroptosis, such as SLC7A11, GPX4 and Nrf2, in oral cancer cells (Fig. 5B). This evidence concerns the gene FTH1 and lip and oral cavity carcinoma.